VANCOUVER, British Columbia, April 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, presented at the American Association of Cancer Research Annual Meeting.
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.